Stock Update (NASDAQ:MACK): Merrimack Pharmaceuticals Inc to Present Updated Overall Survival Analysis of Phase 3 NAPOLI-1 Study of ONIVYDE


Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced that an additional overall survival analysis from the Phase 3 NAPOLI-1 study of ONIVYDE™ (irinotecan liposome injection), also known as “nal-IRI,” in post-gemcitabine metastatic pancreatic cancer will be presented at the American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium (ASCO GI), January 21-23, 2016, at the Moscone West Building in San Francisco.

Merrimack will also present under the “Trials in Progress” category posters on two ongoing front-line metastatic pancreatic cancer studies: ONIVYDE in combination with fluorouracil (5-FU) and leucovorin (LV), with or without the addition of oxaliplatin, versus nab-paclitaxel and gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma, and MM-141, also known as istiratumab, in combination with gemcitabine and nab-paclitaxel in front-line metastatic pancreatic cancer.

Poster Sessions

Session Title: General Poster Session B and Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Friday, January 22, 2016: 12:30 PM-2:00 PM and 5:30 PM-7:00 PM (PT)

  • Updated overall survival analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. (Abstract #417, Board L11)
  • Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. (Abstract #425, Board L19)
  • A randomized, open-label Phase 2 study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC). (Abstract #TPS482, Board O10)
  • A multicenter Phase 2 study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). (Abstract #TPS481, Board O9). (Original Source)

Shares of Merrimack Pharmaceuticals closed last Friday at $6.58, down $0.06 or -0.90%. MACK has a 1-year high of $13.84 and a 1-year low of $6.52. The stock’s 50-day moving average is $8.19 and its 200-day moving average is $9.65.

On the ratings front, Merrimack has been the subject of a number of recent research reports. In a report issued on December 24, Oppenheimer analyst Ling Wang assigned a Buy rating on MACK, with a price target of $15, which implies an upside of 128.0% from current levels. Separately, on December 23, Mizuho’s Eric Criscuolo maintained a Buy rating on the stock and has a price target of $13.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ling Wang and Eric Criscuolo have a total average return of -16.3% and -19.3% respectively. Wang has a success rate of 21.7% and is ranked #3572 out of 3610 analysts, while Criscuolo has a success rate of 14.3% and is ranked #3193.

Merrimack Pharmaceuticals Inc is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer.

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts